{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:54:53Z","timestamp":1789383293195,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":3237,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.ajpath.2010.10.002","type":"journal-article","created":{"date-parts":[[2011,1,29]],"date-time":"2011-01-29T04:17:08Z","timestamp":1296274628000},"page":"525-536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["Arachidonic Acid Pathway Members PLA2G7, HPGD, EPHX2, and CYP4F8 Identified as Putative Novel Therapeutic Targets in Prostate Cancer"],"prefix":"10.1016","volume":"178","author":[{"given":"Paula","family":"Vainio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsi","family":"Ketola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuomas","family":"Mirtti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-Patrick","family":"Mpindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Kohonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidal","family":"Fey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merja","family":"Per\u00e4l\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Verhaegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Schalken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalle A.","family":"Alanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Kallioniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiina","family":"Iljin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2010.10.002_bib1","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2010.10.002_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0002-9440(10)63112-4","article-title":"Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance","volume":"164","author":"Holzbeierlein","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2010.10.002_bib3","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1158\/1078-0432.CCR-06-0067","article-title":"Mechanisms underlying the development of androgen-independent prostate cancer","volume":"12","author":"Pienta","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2010.10.002_bib4","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1172\/JCI31791","article-title":"The evolving biology and treatment of prostate cancer","volume":"117","author":"Taichman","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2010.10.002_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.mce.2008.08.013","article-title":"Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol","volume":"295","author":"Dillard","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ajpath.2010.10.002_bib6","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1158\/0008-5472.CAN-08-4531","article-title":"Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven","volume":"69","author":"Attard","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2010.10.002_bib7","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.juro.2007.12.037","article-title":"The arachidonic acid pathway and its role in prostate cancer development and progression","volume":"179","author":"Patel","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.ajpath.2010.10.002_bib8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/bjc.1991.481","article-title":"Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease","volume":"64","author":"Chaudry","year":"1991","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2010.10.002_bib9","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/jnci\/87.19.1456","article-title":"Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet","volume":"87","author":"Wang","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2010.10.002_bib10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1006\/bbrc.1997.6799","article-title":"Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase","volume":"235","author":"Ghosh","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ajpath.2010.10.002_bib11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/pros.21057","article-title":"Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance","volume":"70","author":"Locke","year":"2010","journal-title":"Prostate"},{"key":"10.1016\/j.ajpath.2010.10.002_bib12","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/ijc.22153","article-title":"What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis?","volume":"119","author":"F\u00fcrstenberger","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2010.10.002_bib13","first-page":"725","article-title":"The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer","volume":"2","author":"Matsuyama","year":"2008","journal-title":"Biologics"},{"key":"10.1016\/j.ajpath.2010.10.002_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc2809","article-title":"Eicosanoids and cancer","volume":"10","author":"Wang","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ajpath.2010.10.002_bib15","doi-asserted-by":"crossref","first-page":"11397","DOI":"10.1074\/jbc.275.15.11397","article-title":"The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2","volume":"275","author":"Hsu","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2010.10.002_bib16","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1158\/1078-0432.CCR-04-0732","article-title":"Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model","volume":"10","author":"Narayanan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2010.10.002_bib17","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1158\/1078-0432.CCR-04-1877","article-title":"Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism","volume":"11","author":"Patel","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2010.10.002_bib18","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.ajpath.2010.10.002_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ijc.20387","article-title":"Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase","volume":"112","author":"Moretti","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2010.10.002_bib20","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1158\/0008-5472.CAN-03-3018","article-title":"Oncogenic action of secreted phospholipase A2 in prostate cancer","volume":"64","author":"Sved","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2010.10.002_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ijc.2910570208","article-title":"Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors","volume":"57","author":"Chaudry","year":"1994","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2010.10.002_bib22","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/ijc.23674","article-title":"Expression and function of fatty acid amide hydrolase in prostate cancer","volume":"123","author":"Endsley","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2010.10.002_bib23","doi-asserted-by":"crossref","first-page":"7750","DOI":"10.1158\/0008-5472.CAN-07-6689","article-title":"Prostaglandin E2 regulates tumor angiogenesis in prostate cancer","volume":"68","author":"Jain","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2010.10.002_bib24","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1186\/gb-2008-9-9-r139","article-title":"Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues","volume":"9","author":"Kilpinen","year":"2008","journal-title":"Genome Biol"},{"key":"10.1016\/j.ajpath.2010.10.002_bib25","doi-asserted-by":"crossref","first-page":"10242","DOI":"10.1158\/0008-5472.CAN-06-1986","article-title":"TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming","volume":"66","author":"Iljin","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2010.10.002_bib26","first-page":"93","article-title":"Androgen receptor in human prostate carcinoma LNCaP\/ADEP cells contains a mutation which alters the specificity of the steroid dependent transcriptional activation region","author":"Harris","year":"1990","journal-title":"Program and Abstracts, 72nd Annual Meeting of the Endocrine Society, Atlanta, GA"},{"key":"10.1016\/j.ajpath.2010.10.002_bib27","first-page":"163","article-title":"VCaP, a cell-based model system of human prostate cancer","volume":"15","author":"Korenchuk","year":"2001","journal-title":"In Vivo"},{"key":"10.1016\/j.ajpath.2010.10.002_bib28","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1177\/1087057103258285","article-title":"Improved statistical methods for hit selection in high-throughput screening","volume":"6","author":"Brideau","year":"2003","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.ajpath.2010.10.002_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1476-5586(04)80047-2","article-title":"ONCOMINE: a cancer microarray database and integrated data-mining platform","volume":"6","author":"Rhodes","year":"2004","journal-title":"Neoplasia"},{"issue":"14","key":"10.1016\/j.ajpath.2010.10.002_bib30","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.2004.05.158","article-title":"Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy","volume":"22","author":"Yu","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2010.10.002_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2005.08.012","article-title":"Oncogenic action of phospholipase A2 in prostate cancer","volume":"240","author":"Dong","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ajpath.2010.10.002_bib32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.prostaglandins.2006.05.022","article-title":"15-Lipoxygenase 2 (15-LOX2) is a functional tumor suppressor that regulates human prostate epithelial cell differentiation, senescence, and growth (size)","volume":"82","author":"Tang","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.ajpath.2010.10.002_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10557-008-6133-8","article-title":"Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2)","volume":"23","author":"Stafforini","year":"2009","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ajpath.2010.10.002_bib34","doi-asserted-by":"crossref","first-page":"21844","DOI":"10.1074\/jbc.M001712200","article-title":"Identification of CYP4F8 in human seminal vesicles as a prominent 19-hydroxylase of prostaglandin endoperoxides","volume":"275","author":"Bylund","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2010.10.002_bib35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10549-008-9927-2","article-title":"Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis [Erratum appeared in Breast Cancer Res Treat 2009, 113:251\u2013252]","volume":"113","author":"Thomassen","year":"2009","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ajpath.2010.10.002_bib36","doi-asserted-by":"crossref","first-page":"7818","DOI":"10.1158\/0008-5472.CAN-05-4368","article-title":"15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer","volume":"66","author":"Wolf","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2010.10.002_bib37","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.1158\/0008-5472.CAN-07-6575","article-title":"15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer","volume":"68","author":"Huang","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2010.10.002_bib38","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1158\/1078-0432.CCR-08-2518","article-title":"15-Hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer","volume":"15","author":"Thiel","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2010.10.002_bib39","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2353\/ajpath.2010.090875","article-title":"Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression","volume":"176","author":"Tseng-Rogenski","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2010.10.002_bib40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1369\/jhc.5A6808.2005","article-title":"Cell-specific subcellular localization of soluble epoxide hydrolase in human tissues","volume":"54","author":"Enayetallah","year":"2006","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.ajpath.2010.10.002_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10735-006-9050-9","article-title":"Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms","volume":"37","author":"Enayetallah","year":"2006","journal-title":"J Mol Histol"},{"key":"10.1016\/j.ajpath.2010.10.002_bib42","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.freeradbiomed.2008.04.034","article-title":"A yeast PAF acetylhydrolase ortholog suppresses oxidative death","volume":"45","author":"Foulks","year":"2008","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.ajpath.2010.10.002_bib43","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/ajcn\/88.3.630","article-title":"Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study","volume":"88","author":"Kim","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.ajpath.2010.10.002_bib44","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1177\/153537020623100903","article-title":"Metallothionein redox cycle and function","volume":"231","author":"Kang","year":"2006","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.ajpath.2010.10.002_bib45","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1158\/1078-0432.CCR-09-1035","article-title":"High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth","volume":"15","author":"Iljin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2010.10.002_bib46","doi-asserted-by":"crossref","first-page":"E375","DOI":"10.1152\/ajpendo.00131.2009","article-title":"Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase","volume":"297","author":"Luria","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ajpath.2010.10.002_bib47","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0090-6980(93)90102-D","article-title":"Identification of 19 (R)-OH prostaglandin E2 as a selective prostanoid EP2-receptor agonist","volume":"46","author":"Woodward","year":"1993","journal-title":"Prostaglandins"},{"key":"10.1016\/j.ajpath.2010.10.002_bib48","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/mc.20320","article-title":"Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway","volume":"46","author":"Wang","year":"2007","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.ajpath.2010.10.002_bib49","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1073\/pnas.0437724100","article-title":"The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity","volume":"100","author":"Newman","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ajpath.2010.10.002_bib50","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0006-2952(95)00167-X","article-title":"Differential regulation of soluble epoxide hydrolase by clofibrate and sexual hormones in the liver and kidneys of mice","volume":"50","author":"Pinot","year":"1995","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ajpath.2010.10.002_bib51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1006\/bbrc.2000.3437","article-title":"Induction of NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase expression by androgens in human prostate cancer cells","volume":"276","author":"Tong","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ajpath.2010.10.002_bib52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1600-0463.2008.00002.x","article-title":"Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality","volume":"117","author":"Mirtti","year":"2009","journal-title":"APMIS"},{"key":"10.1016\/j.ajpath.2010.10.002_bib53","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/ijc.24118","article-title":"Downregulation of vascular endothelial growth factor and induction of tumor dormancy by 15-lipoxygenase-2 in prostate cancer","volume":"124","author":"Tang","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajpath.2010.10.002_bib54","doi-asserted-by":"crossref","first-page":"25091","DOI":"10.1074\/jbc.M301920200","article-title":"Subcellular localization and tumor-suppressive functions of 15-lipoxygenase 2 (15-LOX2) and its splice variants","volume":"278","author":"Bhatia","year":"2003","journal-title":"J Biol Chem"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944010000921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944010000921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:46:12Z","timestamp":1762080372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944010000921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0002944010000921"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2010.10.002","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arachidonic Acid Pathway Members PLA2G7, HPGD, EPHX2, and CYP4F8 Identified as Putative Novel Therapeutic Targets in Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2010.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}